Regenerative Biotechnology
Gencell® CTM Neuromodulatory
Mesenchymal stem cells pretreated with metformin for localized joint and bone repair.
Injectable solution of mesenchymal stem cells pretreated with metformin, designed to promote joint repair, bone regeneration, and inflammatory modulation through targeted intra-articular administration.
Composition
Mesenchymal stem cells pretreated with metformin.
Pharmaceutical form
Injectable solution.
Presentation
Single-dose vial, 4 ml.
Therapeutic properties
Promote joint repair through local immunomodulation, apoptosis inhibition, stimulation of cellular proliferation, chondrogenic and osteogenic support, improved tissue energy metabolism, and inflammation reduction.
- Reduction of local joint inflammation.
- Reduction of joint pain.
- Inhibition of cartilage apoptosis.
- Stimulation of cartilage regeneration.
- Promotion of bone regeneration.
- Supports fracture consolidation.
- Repair of connective tissues.
- Improvement of joint functionality.
Mechanism of action & Clinical data
Integrate into the joint environment, modulate inflammation, inhibit apoptosis and, via OCT-1, increase GLUT2/GLUT4 expression, promoting bone and cartilage regeneration and local energy metabolism.
Indications
Adjunct therapy for non-united fractures, chondral lesions, tendinitis, partial ligament tears, and osteoarthritis.
Administration
Intra-articular administration, direct application of vial content without dilution.
Contraindications
Hypersensitivity or allergy to any component of the formula. Diagnosis of neoplasia.
Storage
Refrigerate between 2–8 °C, protected from direct sunlight. Do not freeze.
